Instead of treating the acquisition as a simple portfolio diversification, Silo is positioning it as a strategic bridge between biotechnology and blockchain innovation. The company believes decentralized science (DeSci) could transform how breakthroughs are funded, shared, and rewarded, offering scientists a transparent alternative to traditional publishing models.
ResearchHub, founded by Coinbase CEO Brian Armstrong in 2019, allows researchers to share findings, peer‑review work, and earn RSC tokens for their contributions. The project has drawn attention for its attempt to “open‑source” the scientific process – removing paywalls and bureaucracy that often slow discovery.
Silo Pharma’s CEO, Eric Weisblum, said the investment represents more than a financial move: it’s a philosophical alignment with the next evolution of research infrastructure. “We see blockchain not only as a financial tool but as a mechanism for accelerating innovation in medicine and beyond,” he explained.
Following Silo’s announcement, ResearchCoin’s price climbed by around 4%, bringing its market capitalization to roughly $60 million. The token is currently listed on Coinbase, where trading volume surged as news of Silo’s involvement spread.
By stepping into the DeSci space, Silo Pharma becomes one of the first biopharma firms to directly support a Web3‑driven research model. It signals a growing trend of traditional science companies embracing blockchain to democratize access to knowledge and potentially fast‑track global collaboration in biomedical discovery.
The information provided in this article is for educational purposes only and does not constitute financial, investment, or trading advice. Coindoo.com does not endorse or recommend any specific investment strategy or cryptocurrency. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.